Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders

@article{Spivak2011HydroxycarbamideAU,
  title={Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders},
  author={J. Spivak and H. Hasselbalch},
  journal={Expert Review of Anticancer Therapy},
  year={2011},
  volume={11},
  pages={403 - 414}
}
Hydroxycarbamide is a nonalkylating antiproliferative and antiviral agent that has been used for over 40 years to treat a variety of neoplastic and non-neoplastic conditions. Hydroxycarbamide is readily absorbed and widely distributed throughout the body. It acts primarily to inhibit DNA synthesis, which underpins its use in solid tumors, viral infections and chronic myeloproliferative disorders. Hydroxycarbamide is an effective treatment for preventing transient ischemic attacks associated… Expand
57 Citations
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
  • 37
The Cell Killing Mechanisms of Hydroxyurea
  • 89
  • PDF
Cutaneous ulcers associated with hydroxyurea therapy.
  • 38
  • PDF
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms
  • 35
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 103 REFERENCES
Hydroxyurea: an overview.
  • M. Stevens
  • Medicine
  • Journal of biological regulators and homeostatic agents
  • 1999
  • 44
Modern treatment strategies in polycythemia vera.
  • 16
Anagrelide: 20 years later
  • 22
  • PDF
Hydroxyurea as a cause of drug fever in essential thrombocythaemia
  • 13
Uncontrolled thrombocytosis in chronic myeloproliferative disorders
  • 92
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
  • 449
...
1
2
3
4
5
...